BioCardia (BCDA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026)
Powered by 
Analysis
BioCardia (BCDA) Net Income towards Common Stockholders Growth (3y) (2016 - 2026) Analysis & Trends
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income Growth (3y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Krystal Biotech | 10.60 Bn | 9.76 Bn | 112.79 Mn | 53.96% |
| 2 | CRISPR Therapeutics AG | 5.39 Bn | 5.39 Bn | - | - |
| 3 | Iovance Biotherapeutics | 3.98 Bn | 3.68 Bn | 55.72 Mn | 23.71% |
| 4 | Legend Biotech | 3.97 Bn | 3.00 Bn | 251.50 Mn | 33.71% |
| 5 | uniQure | 3.09 Bn | 3.09 Bn | 5.49 Mn | - |
| 6 | Beam Therapeutics | 3.06 Bn | 3.06 Bn | - | - |
| 7 | Precigen | 2.54 Bn | 2.54 Bn | 52.17 Mn | - |
| 8 | Sarepta Therapeutics | 2.38 Bn | 1.58 Bn | 251.87 Mn | 41.11% |
| 9 | Vericel | 2.06 Bn | 1.89 Bn | 56.40 Mn | 34.70% |
| 10 | BioCardia | 13.06 Mn | 8.94 Mn | - | 22.24% |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 22.24% |
| Mar 31, 2026 | 13.57% |
| Sep 30, 2025 | 21.36% |
| Jun 30, 2025 | 6.34% |
| Mar 31, 2025 | 6.43% |
| Dec 31, 2024 | -1.53% |
| Sep 30, 2024 | 13.42% |
| Jun 30, 2024 | 22.09% |
| Mar 31, 2024 | 8.52% |
| Dec 31, 2023 | 15.85% |
| Sep 30, 2023 | 12.27% |
| Jun 30, 2023 | 1.13% |
| Mar 31, 2023 | 8.68% |
| Dec 31, 2022 | 5.13% |
| Sep 30, 2022 | 2.87% |
| Jun 30, 2022 | 12.78% |
| Mar 31, 2022 | 3.37% |
| Dec 31, 2021 | 1.86% |
| Sep 30, 2021 | 8.82% |
| Jun 30, 2021 | -2.35% |